Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25648750 | 1.00 | MAPT (0.44) | MAPTMIFALDH1A1USP2ALOX15 | |
| SCHEMBL29084231 | 1.00 | MAPT (0.44) | MAPTMIFALDH1A1USP2ALOX15 | |
| SCHEMBL11680930 | 0.98 | MAPT (0.42) | MAPTMIFALDH1A1USP2ALOX15 | |
| SCHEMBL11680934 | 0.98 | MAPT (0.42) | MAPTMIFALDH1A1USP2ALOX15 | |
| SCHEMBL11747683 | 0.98 | MAPT (0.42) | MAPTMIFALDH1A1USP2ALOX15 | |
| SCHEMBL34475901 | 0.90 | MAPT (0.51) | MAPTALDH1A1USP2ALOX15TDP1 | |
| SCHEMBL16085913 | 0.88 | ALDH1A1 (0.49) | MAPTALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL16085912 | 0.88 | ALDH1A1 (0.49) | MAPTALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL2586974 | 0.86 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4754792 | 0.86 | PPM1B (0.41) | MAPTMIFALDH1A1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302678-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | PROCTER & GAMBLE (US) | 2025-10-02 | — | — | US | claimed |
| US-12350136-B2 | Absorbent articles including perfume and cyclodextrins | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-08 | — | — | US | claimed |
| US-20220401275-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | PROCTER & GAMBLE (US) | 2022-12-22 | — | — | US | claimed |
| US-11458049-B2 | Absorbent articles including perfume and cyclodextrins | THE PROCTER & GAMBLE COMPANY (US) | 2022-10-04 | — | — | US | claimed |
| EP-3509647-B1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | PROCTER & GAMBLE (US) | 2020-10-21 | — | — | EP | claimed |
| EP-3509647-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | The Procter and Gamble Company (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018048852-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | THE PROCTER & GAMBLE COMPANY (US) | 2018-03-15 | — | — | WO | claimed |
| US-20180064588-A1 | Absorbent Articles Including Perfume and Cyclodextrins | THE PROCTER & GAMBLE COMPANY | 2018-03-08 | — | — | US | claimed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260102294-A1 | ABSORBENT ARTICLE COMPRISING A FRAGRANCE AND AN ODOR CONTROL COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-16 | — | — | US | disclosed |
| US-12533269-B2 | Absorbent article comprising a fragrance and an odor control composition | THE PROCTER & GAMBLE COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250302678-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | PROCTER & GAMBLE (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-12350136-B2 | Absorbent articles including perfume and cyclodextrins | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-0479166-A1 | Transesterification process for preparation of cycloaliphatic epoxides | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0219154-B1 | FURYL COMPOUNDS, THEIR USE AS FUNGICIDES AND THEIR PREPARATION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-11-13 | — | — | EP | disclosed |
| EP-0219154-A2 | Furyl compounds, their use as fungicides and their preparation | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-04-22 | — | — | EP | disclosed |
| US-4562256-A | HYPOTENSIVE AGENTS | SHIONOGI & CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4246199-A | ACID CATALYZED REACTION OF A CARBONIUM ION COMPONENT AND A NITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-20 | — | — | US | disclosed |
| US-3980738-A | Process for the preparation of (thio)phosphoric (phosphonic) acid esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533269-B2 | Absorbent article comprising a fragrance and an odor control composition | CUTA, CFD, MBTD1 | MAPT 647/4885MIF 223/4885ALDH1A1 1162/4885 |
| US-20260102294-A1 | ABSORBENT ARTICLE COMPRISING A FRAGRANCE AND AN ODOR CONTROL COMPOSITION | CUTA, SHBG, DSG1 | MAPT 1088/4885MIF 656/4885ALDH1A1 1516/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | MAPT 1959/4885MIF 4261/4885ALDH1A1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.